questionText: To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of Teplizumab in slowing the development of type 1 diabetes; and when he plans to roll-out that drug on the NHS.
answerText: Teplizumab was licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) in August 2025, to delay the onset of Stage 3 type 1 diabetes in adult and paediatric patients 8 years of age and older with Stage 2 type 1 diabetes. Newly licensed ...
heading: Teplizumab